Oosthuizen Johannes Jacobus

Merck President U.S. Market sells 15,000 MRK shares at $121.87; stock near 52-week high ($121.93).

Oosthuizen Johannes Jacobus, President of U.S. Market at Merck & Co., Inc., sold 15,000 shares at $121.87 on 2026-02-06, reducing his holdings from 36,197 shares to 21,197 shares—a 41.4% reduction in position size. The sale occurred at a price only $0.06 below the 52-week high of $121.93, in the context of a strong near-term rally: MRK gained 12.3% over the prior 30 days and 41.3% over 90 days. Across his prior two sales at MRK specifically, the insider's timing record is mixed: the 2025-02-19 sale was followed by a 90-day decline (-7.3%, well-timed), while the 2024-02-02 sale was followed by a slight 90-day gain (+0.8%, poorly-timed). His cross-ticker track record shows a 50.00% well-timed rate on 2 prior sales with a negative 90-day average return of -3.2%, suggesting selective execution but no consistent pattern of predictive timing.

Merck President Oosthuizen sells 8,500 shares at $84.09; stock down -34.1% from 52-week high, -21.7% of his holdings.

Oosthuizen Johannes Jacobus (President, U.S. Market) sold 8,500 shares of Merck & Co., Inc. (MRK) at $84.09 on 2025-02-19, reducing his position from 39.2K shares to 30.7K shares. The sale occurs against a backdrop of material stock weakness: MRK is trading -34.1% below its 52-week high of $132.96 and has declined -8.9% over the past 30 days. However, his cross-ticker track record shows limited predictive signal—only 1 prior open-market sell with a 90-day outcome that was poorly timed (the stock rose +0.8% afterward), yielding a 0.00% well-timed rate. At the same ticker, his prior sale on 2024-02-02 similarly failed to precede gains (90d return +0.8%). The company's fundamentals remain stable: $16.7B quarterly revenue, $3.2B net income, and a P/E of 18.27. The sale is sized at approximately 21.7% of pre-transaction holdings, which is material but does not constitute a complete exit, leaving him with substantial MRK exposure.